Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

News SummaryMost relevantAll newsSector newsTweets

Regeneron Pharmaceuticals : Sanofi beats profit forecasts, upbeat on prospects for eczema drug

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2017 | 10:30am CEST
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

The results were buoyed by Sanofi's speciality care division Genzyme, as well as vaccines and consumer products it has acquired from Germany's Boehringer Ingelheim.

Earlier this year, Sanofi had warned investors it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges.

The company had also said in 2015 it was not targeting any 'meaningful' profit growth for two years, citing difficulties in its embattled diabetes division.

"Although it has now some margin to deliver actual numbers above guidance, Sanofi also has reasons to wait a bit more before raising it. Diabetes is still a very uncertain market segment to work in," Bryan Garnier analysts said in a note.

However, Sanofi, whose shares were up more than 2 percent at 0805 GMT, said it was confident Dupixent, a drug for moderate-to-severe atopic dermatitis that was approved in the United States at the end of last month, would sell well.

Analysts forecast annual Dupixent sales of more than $4 billion (£3.10 billion) by 2022, according to Thomson Reuters data. Developed with Regeneron (>> Regeneron Pharmaceuticals Inc), the drug is seen as the most important growth driver for the two companies, who have said Dupixent will have a list price of $37,000 a year.

Sanofi Chief Executive Olivier Brandicourt told journalists that he was "very encouraged with the early coverage" of Dupixent, adding that "the launch is delivering so far exactly on our expectations".

While the price of Dupixent before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about $50,000 a year.


Sanofi said on Friday first-quarter business net income rose 1 percent at constant exchange rates to 1.8 billion euros (£1.51 billion). Total sales rose 8.6 percent to 8.65 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.6 billion euros and net sales of 8.38 billion.

Genzyme's sales were up 15.5 percent while revenue at the vaccines divisions rose 22.2 percent. Consumer healthcare products sales were up 42.7 percent.

Hurt by continued U.S. pricing pressure, diabetes and cardiovascular sales however suffered another downturn with revenue falling 7.7 percent.

(Additional reporting by Matthieu Protard; Editing by Leigh Thomas and Alexander Smith)

By Matthias Blamont

Stocks treated in this article : Sanofi, Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
09/21 REGENERON PHARMACEUTICALS : Important Note Regarding the September 11, 2017 Pres..
09/21 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupilumab Topline Resul..
09/19 SANOFI : and Regeneron Announce Positive Study Results for Dupixent in Patients ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/14 REGENERON PHARMACEUTICALS : and Sanofi Announce Cemiplimab REGN2810 Has Received..
09/14 REGENERON PHARMACEUTICALS : `s Dupixent Takes Another Step Toward Blockbuster St..
09/14 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Submission of Matters ..
09/13 REGENERON PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders ..
More news
News from SeekingAlpha
09/21 Esperion Therapeutics Remains Undervalued
09/19 YOUR DAILY PHARMA SCOOP : Nabriva's Further Potential, Allergan's IP Gimmick, Su..
09/19 Biotech And Pharma Stocks To Soak Up At The Bottom
09/18 Regeneron and Sanofi's Dupixent shows positive effect in dermatitis patients ..
09/18 Regeneron - Diversification Efforts Could Soon Yield Results
Financials ($)
Sales 2017 5 747 M
EBIT 2017 2 392 M
Net income 2017 1 331 M
Finance 2017 2 285 M
Yield 2017 -
P/E ratio 2017 37,78
P/E ratio 2018 34,09
EV / Sales 2017 7,68x
EV / Sales 2018 6,77x
Capitalization 46 445 M
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 496 $
Spread / Average Target 14%
EPS Revisions
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN28.70%136 186
GILEAD SCIENCES15.40%107 896
ACTELION21.20%29 716